

Emptying the stores: lysosomal diseases and therapeutic

Nature Reviews Drug Discovery

17, 133-150

DOI: [10.1038/nrd.2017.214](https://doi.org/10.1038/nrd.2017.214)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Molecular regulations and therapeutic targets of Gaucher disease. Cytokine and Growth Factor Reviews, 2018, 41, 65-74.	3.2	13
2	The Golgi complex in disease and therapy. Current Opinion in Cell Biology, 2018, 50, 102-116.	2.6	65
3	Gadolinium Chloride Rescues Niemann-Pick Type C Liver Damage. International Journal of Molecular Sciences, 2018, 19, 3599.	1.8	4
4	Getting the Most: Enhancing Efficacy by Promoting Erythropoiesis and Thrombopoiesis after Gene Therapy in Mice with Hurler Syndrome. Molecular Therapy - Methods and Clinical Development, 2018, 11, 52-64.	1.8	1
5	Locally anchoring enzymes to tissues via extracellular glycan recognition. Nature Communications, 2018, 9, 4943.	5.8	30
6	Brain-penetrant heat shock protein amplifier arimoclomol enhances GCase activity in in vitro Gaucher disease models. EBioMedicine, 2018, 38, 7-8.	2.7	0
7	Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Human Molecular Genetics, 2018, 27, 3392-3403.	1.4	34
8	Emerging concepts of ganglioside metabolism. FEBS Letters, 2018, 592, 3835-3864.	1.3	72
9	Alpha-Mannosidosis: Therapeutic Strategies. International Journal of Molecular Sciences, 2018, 19, 1500.	1.8	32
10	The GM2 ganglioside inhibits iNKT cell responses in a CD1d-dependent manner. Molecular Genetics and Metabolism, 2018, 125, 161-167.	0.5	4
11	Getting to the Heart of the Matter: Lysosomal Storage Diseases That Manifest a Cardiac Phenotype. Current Genetic Medicine Reports, 2018, 6, 28-42.	1.9	2
12	Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials. Orphanet Journal of Rare Diseases, 2018, 13, 143.	1.2	41
13	Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 2018, 17, 660-688.	21.5	370
14	Defective collagen proteostasis and matrix formation in the pathogenesis of lysosomal storage disorders. Matrix Biology, 2018, 71-72, 283-293.	1.5	18
15	Crystal structure of arginine-bound lysosomal transporter SLC38A9 in the cytosol-open state. Nature Structural and Molecular Biology, 2018, 25, 522-527.	3.6	45
16	Recent advances in lysosome-targeting luminescent transition metal complexes. Coordination Chemistry Reviews, 2019, 398, 113010.	9.5	45
17	Prenatal enzymatic diagnosis of lysosomal storage diseases using cultured amniotic cells, uncultured chorionic villus samples, and fetal blood cells: Hacettepe experience. Prenatal Diagnosis, 2019, 39, 1080-1085.	1.1	1
18	Lysosome imaging in cancer cells by pyrene-benzothiazolium dyes: An alternative imaging approach for LAMP-1 expression based visualization methods to avoid background interference. Bioorganic Chemistry, 2019, 91, 103144.	2.0	14

#	ARTICLE	IF	CITATIONS
19	Evaluation of Lipid Accumulation Using Electrical Impedance Measurement under Three-Dimensional Culture Condition. <i>Micromachines</i> , 2019, 10, 455.	1.4	3
20	Strategies to target bioactive molecules to subcellular compartments. Focus on natural compounds. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111557.	2.6	20
21	Rats deficient in β -galactosidase A develop ocular manifestations of Fabry disease. <i>Scientific Reports</i> , 2019, 9, 9392.	1.6	9
22	Advances in the treatment of neuronal ceroid lipofuscinosis. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 473-500.	0.5	20
23	Lysosomes as a therapeutic target. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 923-948.	21.5	413
24	Selective Targeting of the Interconversion between Glucosylceramide and Ceramide by Scaffold Tailoring of Iminosugar Inhibitors. <i>Molecules</i> , 2019, 24, 354.	1.7	5
25	Novel Therapies for Orphan Diseases. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1020-1023.	1.3	9
26	Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1264.	2.2	10
27	Lysosomal Glycosphingolipid Storage Diseases. <i>Annual Review of Biochemistry</i> , 2019, 88, 461-485.	5.0	78
28	Pharmacological Chaperones for the Treatment of β -Mannosidosis. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5832-5843.	2.9	25
29	The glycosylation design space for recombinant lysosomal replacement enzymes produced in CHO cells. <i>Nature Communications</i> , 2019, 10, 1785.	5.8	49
30	Animal models for Niemann-Pick type C: implications for drug discovery & development. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 499-509.	2.5	34
31	Red-emitting pyrene- β -benzothiazolium: unexpected selectivity to lysosomes for real-time cell imaging without alkalinizing effect. <i>Chemical Communications</i> , 2019, 55, 3469-3472.	2.2	30
32	Lysosome motility and distribution: Relevance in health and disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1076-1087.	1.8	51
33	Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. <i>Molecular Brain</i> , 2019, 12, 100.	1.3	122
34	Inflammatory response and its relation to sphingolipid metabolism proteins: Chaperones as potential indirect anti-inflammatory agents. <i>Advances in Protein Chemistry and Structural Biology</i> , 2019, 114, 153-219.	1.0	7
35	Lysosomal storage disorders – challenges, concepts and avenues for therapy: beyond rare diseases. <i>Journal of Cell Science</i> , 2019, 132, jcs221739.	1.2	141
36	Progress in the understanding and treatment of Fabry disease. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129437.	1.1	73

#	ARTICLE	IF	CITATIONS
37	Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses. International Journal of Molecular Sciences, 2020, 21, 232.	1.8	22
38	Novel compounds that reverse the disease phenotype in Type 2 Gaucher disease patient-derived cells. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126806.	1.0	3
39	Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. Parkinsonism and Related Disorders, 2020, 73, 60-71.	1.1	85
40	Impact of the organic cation transporter 2 inhibitor cimetidine on the single-dose pharmacokinetics of the glucosylceramide synthase inhibitor lucerastat in healthy subjects. European Journal of Clinical Pharmacology, 2020, 76, 431-437.	0.8	6
41	Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nature Reviews Drug Discovery, 2020, 19, 93-111.	21.5	190
42	Lysosomes as dynamic regulators of cell and organismal homeostasis. Nature Reviews Molecular Cell Biology, 2020, 21, 101-118.	16.1	757
43	A novel fluorescent protein chromophore analogue to simultaneously probe lysosome viscosity and β -amyloid fibrils. Sensors and Actuators B: Chemical, 2020, 305, 127509.	4.0	32
44	Cathepsin K is a potent disaggregase of β -synuclein fibrils. Biochemical and Biophysical Research Communications, 2020, 529, 1106-1111.	1.0	11
45	Deregulation of signalling in genetic conditions affecting the lysosomal metabolism of cholesterol and galactosyl-sphingolipids. Neurobiology of Disease, 2020, 146, 105142.	2.1	6
46	Therapeutic advances in Fabry disease: The future awaits. Biomedicine and Pharmacotherapy, 2020, 131, 110779.	2.5	19
47	Bis(monoacylglycero)phosphate, a new lipid signature of endosome-derived extracellular vesicles. Biochimie, 2020, 178, 26-38.	1.3	24
48	β -Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome. Science China Life Sciences, 2020, 63, 1850-1859.	2.3	16
49	CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges. Frontiers in Molecular Biosciences, 2020, 7, 559804.	1.6	38
50	Understanding and Treating Niemann-Pick Type C Disease: Models Matter. International Journal of Molecular Sciences, 2020, 21, 8979.	1.8	20
51	Endosomal-lysosomal dysfunction in metabolic diseases and Alzheimer's disease. International Review of Neurobiology, 2020, 154, 303-324.	0.9	14
52	Glycoside hydrolase stabilization of transition state charge: new directions for inhibitor design. Chemical Science, 2020, 11, 10488-10495.	3.7	12
53	Concise asymmetric synthesis of new enantiomeric <i>N</i> -alkyl pyrrolidines acting as pharmacological chaperones against Gaucher disease. Organic and Biomolecular Chemistry, 2020, 18, 7852-7861.	1.5	12
55	Allosteric regulation of lysosomal enzyme recognition by the cation-independent mannose 6-phosphate receptor. Communications Biology, 2020, 3, 498.	2.0	20

#	ARTICLE	IF	CITATIONS
56	Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5732.	1.8	5
57	Repurposing Cationic Amphiphilic Drugs and Derivatives to Engage Lysosomal Cell Death in Cancer Treatment. <i>Frontiers in Oncology</i> , 2020, 10, 605361.	1.3	16
58	Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock. <i>Frontiers in Neuroscience</i> , 2020, 14, 580179.	1.4	42
59	Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience. <i>Molecular Genetics and Metabolism</i> , 2020, 130, 170-171.	0.5	44
60	Super-resolution observation of lysosomal dynamics with fluorescent gold nanoparticles. <i>Theranostics</i> , 2020, 10, 6072-6081.	4.6	43
61	Tolerance induction and microglial engraftment after fetal therapy without conditioning in mice with mucopolysaccharidosis type VII. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	24
62	Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses. <i>International Journal of Molecular Sciences</i> , 2020, 21, 400.	1.8	34
63	Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity. <i>Diagnostics</i> , 2020, 10, 58.	1.3	4
64	Inhibition of endogenous miR-23a/miR-377 in CHO cells enhances difficult-to-express recombinant lysosomal sulfatase activity. <i>Biotechnology Progress</i> , 2020, 36, e2974.	1.3	7
65	SnapShot: Lysosomal Storage Diseases. <i>Cell</i> , 2020, 180, 602-602.e1.	13.5	16
66	Cln1 mutations suppress Rab7-RILP interaction and impair autophagy contributing to neuropathology in a mouse model of infantile neuronal ceroid lipofuscinosis. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1082-1101.	1.7	16
67	A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia. <i>Heliyon</i> , 2020, 6, e03635.	1.4	6
68	From nucleus to mitochondria to lysosome selectivity switching in a cyanine probe: The phenolic to methoxy substituent conversion affects probe's selectivity. <i>Bioorganic Chemistry</i> , 2020, 99, 103848.	2.0	16
69	Functional Study of Novel Bartter's Syndrome Mutations in CLC-Kb and Rescue by the Accessory Subunit Barttin Toward Personalized Medicine. <i>Frontiers in Pharmacology</i> , 2020, 11, 327.	1.6	6
70	Unraveling the mystery of Gaucher bone density pathophysiology. <i>Molecular Genetics and Metabolism</i> , 2021, 132, 76-85.	0.5	7
71	Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. <i>Drugs</i> , 2021, 81, 101-123.	4.9	35
72	Selective autophagy of intracellular organelles: Recent research advances. <i>Theranostics</i> , 2021, 11, 222-256.	4.6	207
73	Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1684.	3.3	12

#	ARTICLE	IF	CITATIONS
74	Endolysosomal Disorders Affecting the Proximal Tubule of the Kidney: New Mechanistic Insights and Therapeutics. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2021, , 233-257.	0.9	2
75	Biosynthesis of Glycolipids. , 2021, , 117-126.		0
76	Chemoenzymatic glycan-selective remodeling of a therapeutic lysosomal enzyme with high-affinity M6P-glycan ligands. Enzyme substrate specificity is the name of the game. <i>Chemical Science</i> , 2021, 12, 12451-12462.	3.7	5
77	Endogenous Mechanisms of Neuroprotection: To Boost or Not to Be. <i>Cells</i> , 2021, 10, 370.	1.8	10
78	Lysosomal Stress Response (LSR): Physiological Importance and Pathological Relevance. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 219-237.	2.1	31
79	Lysosome (Dys)function in Atherosclerosisâ€”A Big Weight on the Shoulders of a Small Organelle. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 658995.	1.8	21
80	Virus-Derived Peptides for Hepatic Enzyme Delivery. <i>Molecular Pharmaceutics</i> , 2021, 18, 2004-2014.	2.3	1
81	Editorial: The Dynamic Interplay Between Nutrition, Autophagy and Cell Metabolism. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 684049.	1.8	0
82	Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. <i>Current Molecular Medicine</i> , 2021, 21, 111-132.	0.6	5
84	Role of lysosomes in physiological activities, diseases, and therapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 79.	6.9	98
85	Stereoselective synthesis of a 4- β -glucoside of valienamine and its X-ray structure in complex with <i>Streptomyces coelicolor</i> GlgE1-V279S. <i>Scientific Reports</i> , 2021, 11, 13413.	1.6	3
87	A GH89 human β -N-acetylglucosaminidase (hNAGLU) homologue from gut microbe <i>Bacteroides thetaiotaomicron</i> capable of hydrolyzing heparosan oligosaccharides. <i>AMB Express</i> , 2021, 11, 94.	1.4	0
88	Reconstruction of the Cytokine Signaling in Lysosomal Storage Diseases by Literature Mining and Network Analysis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 703489.	1.8	4
89	Myelin Defects in Niemannâ€”Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8858.	1.8	11
90	Lysosomes in acute myeloid leukemia: potential therapeutic targets?. <i>Leukemia</i> , 2021, 35, 2759-2770.	3.3	18
91	Design and Validation of a Custom NGS Panel Targeting a Set of Lysosomal Storage Diseases Candidate for NBS Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10064.	1.8	11
92	Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 624988.	1.6	21
93	Recent advances in ruthenium(II) and iridium(III) complexes containing nanosystems for cancer treatment and bioimaging. <i>Coordination Chemistry Reviews</i> , 2021, 443, 214016.	9.5	68

#	ARTICLE	IF	CITATIONS
94	Pathogenesis and Molecular Mechanisms of Anderson's Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies. International Journal of Molecular Sciences, 2021, 22, 10088.	1.8	26
95	The rapidly evolving view of lysosomal storage diseases. EMBO Molecular Medicine, 2021, 13, e12836.	3.3	118
97	A kinase cascade on the yeast lysosomal vacuole regulates its membrane dynamics: conserved kinase Env7 is phosphorylated by casein kinase Yck3. Journal of Biological Chemistry, 2020, 295, 12262-12278.	1.6	4
99	Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder. JCI Insight, 2019, 4, .	2.3	14
100	Treatment for Lysosomal Storage Disorders. Current Pharmaceutical Design, 2020, 26, 5110-5118.	0.9	12
102	A Comprehensive, Targeted NGS Approach to Assessing Molecular Diagnosis of Lysosomal Storage Diseases. Genes, 2021, 12, 1750.	1.0	3
103	Acid ceramidase deficiency: Farber lipogranulomatosis, spinal muscular atrophy associated with progressive myoclonic epilepsy and peripheral osteolysis. , 2020, , 547-557.		0
105	Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduction and Targeted Therapy, 2021, 6, 379.	7.1	58
106	Targeting neurological abnormalities in lysosomal storage diseases. Trends in Pharmacological Sciences, 2022, 43, 495-509.	4.0	5
108	Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease. Cell Transplantation, 2021, 30, 096368972110602.	1.2	3
109	Benzothiazole based fluorescent probes for the detection of biomolecules, physiological conditions, and ions responsible for diseases. Dyes and Pigments, 2022, 199, 110074.	2.0	30
110	Newborn Screening. , 2021, , .		0
111	Approach to the Child With Dysmorphism. , 2021, , .		0
112	Defective Cystinosin, Aberrant Autophagy's Endolysosome Pathways, and Storage Disease: Towards Assembling the Puzzle. Cells, 2022, 11, 326.	1.8	2
113	TRPMLs and TPCs: Targets for lysosomal storage and neurodegenerative disease therapy?. Cell Calcium, 2022, 103, 102553.	1.1	14
114	<i>Hgs</i> Deficiency Caused Restrictive Cardiomyopathy via Disrupting Proteostasis. International Journal of Biological Sciences, 2022, 18, 2018-2031.	2.6	0
115	Recent advances in noble metal complex based photodynamic therapy. Chemical Science, 2022, 13, 5085-5106.	3.7	62
116	Neurophysiological Findings in Neuronal Ceroid Lipofuscinoses. Frontiers in Neurology, 2022, 13, 845877.	1.1	7

#	ARTICLE	IF	CITATIONS
117	Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. <i>Cardiology and Therapy</i> , 2022, 11, 203-230.	1.1	4
118	Small molecule inhibitors of mammalian glycosylation. <i>Matrix Biology Plus</i> , 2022, 16, 100108.	1.9	6
119	Neuronal genetic rescue normalizes brain network dynamics in a lysosomal storage disorder despite persistent storage accumulation. <i>Molecular Therapy</i> , 2022, 30, 2464-2473.	3.7	4
120	Mutation of SLC7A14 causes auditory neuropathy and retinitis pigmentosa mediated by lysosomal dysfunction. <i>Science Advances</i> , 2022, 8, eabk0942.	4.7	7
121	Lysosome-Targeting Strategy Using Polypeptides and Chimeric Molecules. <i>ACS Omega</i> , 2022, 7, 5-16.	1.6	8
122	A Compendium of Information on the Lysosome. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 798262.	1.8	22
123	Lysosomes in Stem Cell Quiescence: A Potential Therapeutic Target in Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 1618.	1.7	5
124	Evolving therapies in neuronopathic LSDs: opportunities and challenges. <i>Metabolic Brain Disease</i> , 2022, 37, 2245-2256.	1.4	5
125	Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases. , 2022, 1, 156-162.		3
130	Lysosome-targeting luminescent lanthanide complexes: from molecular design to bioimaging. <i>Dalton Transactions</i> , 2022, 51, 7748-7762.	1.6	14
131	sp ² -Iminosugars targeting human lysosomal Î²-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1364-1374.	2.5	5
132	Nanodrugs Detonate Lysosome Bombs. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	3
133	Recent Insight into the Genetic Basis, Clinical Features, and Diagnostic Methods for Neuronal Ceroid Lipofuscinosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5729.	1.8	7
134	Stereoselective Synthesis of Nojirimycin Î±-Glycosides from a Bicyclic Acyliminium Intermediate: A Convenient Entry to N-,C-Biantennary Glycomimetics. <i>ACS Omega</i> , 0, , .	1.6	2
135	Lysosome Interference Enabled by Protonâ€Driven Dynamic Assembly of DNA Nanoframeworks inside Cells. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	25
136	Treatment of Neuronopathic Mucopolysaccharidoses with Bloodâ€Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis. <i>Pharmaceutics</i> , 2022, 14, 1240.	2.0	9
137	Lysosome Interference Enabled by Protonâ€Driven Dynamic Assembly of DNA Nanoframework inside Cells. <i>Angewandte Chemie</i> , 0, , .	1.6	0
138	Using analogue data to substantiate long-term durability of gene therapies: a narrative review. <i>Regenerative Medicine</i> , 0, , .	0.8	0

#	ARTICLE	IF	CITATIONS
139	Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. <i>Advanced Drug Delivery Reviews</i> , 2022, 187, 114402.	6.6	20
140	Loss of KEAP1 Causes an Accumulation of Nondegradative Organelles. <i>Antioxidants</i> , 2022, 11, 1398.	2.2	5
141	Ultralong-Term Super-Resolution Tracking of Lysosomes in Brain Organoids by Near-Infrared Noble Metal Nanoclusters. , 2022, 4, 1565-1573.		12
142	Pharmacological Chaperones for GCCase that Switch Conformation with pH Enhance Enzyme Levels in Gaucher Animal Models. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	4
143	Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114464.	6.6	14
144	Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114465.	6.6	17
145	Detection of Structural Variants by NGS: Revealing Missing Alleles in Lysosomal Storage Diseases. <i>Biomedicines</i> , 2022, 10, 1836.	1.4	0
146	Pharmacological Chaperones for GCCase that Switch Conformation with pH Enhance Enzyme Levels in Gaucher Animal Models. <i>Angewandte Chemie</i> , 0, , .	1.6	0
147	Use of acidic nanoparticles to rescue macrophage lysosomal dysfunction in atherosclerosis. <i>Autophagy</i> , 2023, 19, 886-903.	4.3	11
148	Drug delivery systems in Krabbe diseaseâ€™present and prospective approaches. , 2022, , 317-336.		0
149	Advanced drug delivery systems in the management of Gaucher disease. , 2022, , 137-148.		0
150	The Role of the miR-17-92 Cluster in Autophagy and Atherosclerosis Supports Its Link to Lysosomal Storage Diseases. <i>Cells</i> , 2022, 11, 2991.	1.8	1
151	The use of pharmacological chaperones in rare diseases caused by reduced protein stability. <i>Proteomics</i> , 2022, 22, .	1.3	4
152	The Finnish genetic heritage in 2022 â€™ from diagnosis to translational research. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	7
153	Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia. <i>Trends in Cell Biology</i> , 2023, 33, 324-339.	3.6	30
154	Lysosomal Targeting of Î²â€™Cyclodextrin. <i>Chemistry - A European Journal</i> , 0, , .	1.7	3
155	In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompeâ€™s Disease. <i>New England Journal of Medicine</i> , 2022, 387, 2150-2158.	13.9	32
156	Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3â€™years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. <i>Molecular Genetics and Metabolism</i> , 2023, 138, 106963.	0.5	12

#	ARTICLE	IF	CITATIONS
157	Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses. <i>Advanced Drug Delivery Reviews</i> , 2022, 191, 114616.	6.6	4
158	Galactosyl- and glucosylsphingosine induce lysosomal membrane permeabilization and cell death in cancer cells. <i>PLoS ONE</i> , 2022, 17, e0277058.	1.1	4
159	Therapeutics in Metabolic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 255-273.	0.8	0
160	From Lysosomal Storage Disorders to Parkinsonâ€™s Disease â€“ Challenges and Opportunities. <i>Journal of Molecular Biology</i> , 2023, 435, 167932.	2.0	3
161	Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders. <i>Advanced Drug Delivery Reviews</i> , 2023, 197, 114683.	6.6	8
162	The Biology of Lysosomes: From Order to Disorder. <i>Biomedicines</i> , 2023, 11, 213.	1.4	4
163	Genetic causes of heart failure with preserved ejection fraction: emerging pharmacological treatments. <i>European Heart Journal</i> , 2023, 44, 656-667.	1.0	11
164	Expert-opinion-based guidance for the care of children with lysosomal storage diseases during the COVID-19 pandemic: An experience-based Turkey perspective. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	0
165	The role of lysosomes in metabolic and autoimmune diseases. <i>Nature Reviews Nephrology</i> , 2023, 19, 366-383.	4.1	20
167	Lysosome-targeted multifunctional lipid probes reveal the sterol transporter NPC1 as a sphingosine interactor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	12
168	Construction of Polymeric DNA Network and Application for Cell Manipulation. <i>Chinese Journal of Chemistry</i> , 2023, 41, 1875-1887.	2.6	1
169	Advances in Drug Discovery Targeting Lysosomal Membrane Proteins. <i>Pharmaceuticals</i> , 2023, 16, 601.	1.7	2
179	Gene Therapy of Extracellular Vesicles in Cardiovascular and Metabolic Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 207-228.	0.8	0
184	Experimental Models of CNS Disorders Related to Lysosomal Storage Diseases. <i>Journal of Evolutionary Biochemistry and Physiology</i> , 2023, 59, 2072-2085.	0.2	0
191	Glycosphingolipids and central nervous systemâ€™related diseases. , 2024, , 243-351.		0